Glaxo to raise India unit stake in Rs 5,220-cr deal

Glaxo said it will acquire 13,389,410 equity shares representing 31.84% of the company at Rs 3,900 a share

Image
Reuters Mumbai
Last Updated : Jan 20 2013 | 6:29 AM IST

Don't want to miss the best from Business Standard?

GlaxoSmithKline Plcplans to buy up to an additional 31.8 percent stake in its Indian consumer products arm for about Rs 5,220 crore, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint.

GlaxoSmithKline plans to raise its stake in GlaxoSmithKline Consumer Healthcare Ltd to 75% from 43.2%, paying Rs 3,900 per share through an open offer, it said in a statement.

The price represents a premium of 28% to the stock's Friday close.

The news sent shares of GSK Consumer Healthcare to a record high. The shares were locked at Rs 3,659.20, up 20%, their maximum daily trading limit, while the Mumbai market was up 0.23%, by 11:30 am.

"This transaction represents a further step in GSK's strategy to invest in the world's fastest growing markets," David Redfern, chief strategy officer at GlaxoSmithKline, said in the statement.

The company, however, has "no current plans" to launch an open offer for its Indian drugs unit GlaxoSmithKline Pharmaceuticals Ltd, he added.

Horlicks plan

Tough market conditions in Europe have hampered GSK's hopes for a return to sales growth this year, although the company's growing business in emerging markets and its large consumer healthcare operation are both doing well.

In India, for example, sales of the consumer unit's flagship Horlicks brand stood at 270 million pounds in the year that ended December 2011, contributing to nearly three-quarters of its total revenues.

"A lot of the current business of Horlicks is in the south and the east of India. So there is still a great opportunity to increase the penetration to the north and the west," Redfern told Reuters in an interview, adding that the company intended to introduce new variants of the brand in the country.

GlaxoSmithKline does not plan to delist the unit.

Securities regulations in India require a minimum public shareholding of 25 percent for a company to maintain a public listing.

The offer period is expected to begin in January 2013. 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 26 2012 | 9:46 AM IST

Next Story